ArticleAdvances in radiation oncology2026
Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Radical cystectomy with neoadjuvant cisplatin-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, recurrence remains common. Postoperative radiation therapy (PORT) has been explored to improve locoregional control and survival, but evidence remains inconclusive. This systematic review and meta-analysis assessed the role of PORT in MIBC. Methods and Materials: PubMed, Embase, and Cochrane were searched through March 2025 (CRD42025632052). Eligible studies included randomized controlled trials (RCTs), prospective nonrandomized studies, and comparative observational cohorts of patients with MIBC undergoing radical cystectomy, with or without PORT. Prospective single-arm studies of PORT were included for safety outcomes. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS); secondary outcomes included locoregional recurrence (LRR) and treatment-related toxicities. Random-effects models were used. Results: Fifteen studies (5 RCTs, 2 prospective nonrandomized, and 8 retrospective cohorts) were included. A total of 19,033 patients (PORT, 1157) were included in the comparative analysis. PORT was associated with improved OS (hazard ratio, 0.84; 95% CI, 0.71-0.98; Conclusions: PORT reduced LRR across all analyses, improved OS in the overall and RCT-only analysis, and showed RFS benefits in sensitivity, urothelial-only, and RCT-only analyses. PORT may benefit selected high-risk patients, and its integration with contemporary radiation and systemic therapies warrants further prospective evaluation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.